Xeris launches Ph2 trial of ready-to-use liquid glucagon

This article was originally published here

Xeris Pharmaceuticals - updatedXeris Pharmaceuticals (NSDQ:XERS) said today that it dosed the first patients in a Phase II trial of its ready-to-use liquid glucagon in people with Type 1 diabetes.

The Chicago-based company expects to report top-line data from the study in the second half of 2019.

Get the full story at our sister site, Drug Delivery Business News.

The post Xeris launches Ph2 trial of ready-to-use liquid glucagon appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply